Core Viewpoint - The stock of Jinyu Biotechnology Co., Ltd. experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 20% over three consecutive trading days from July 15 to July 17, 2025, triggering the abnormal fluctuation standards set by the Shanghai Stock Exchange [2][3]. Group 1: Stock Trading Abnormalities - The stock price of Jinyu Biotechnology rose significantly, with a cumulative increase of over 20% during the specified trading days [2][3]. - The company confirmed that its production and operational conditions remain normal, with no significant changes in the external business environment [4]. Group 2: Financial Performance - The company anticipates a net profit attributable to shareholders of between 57 million to 70 million yuan for the first half of 2025, representing a decrease of 52.92 million to 65.92 million yuan compared to the same period last year, which is a year-on-year decline of 43.05% to 53.63% [4]. - The expected net profit after deducting non-recurring gains and losses is projected to be between 30 million to 44 million yuan, reflecting a decrease of 63.86 million to 77.86 million yuan year-on-year, a decline of 59.21% to 72.19% [4]. Group 3: Major Events and Developments - The company’s wholly-owned subsidiary, Jinyu Baoling, received a clinical trial approval for an African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs [5][12]. - The vaccine development has involved a cumulative investment of approximately 64 million yuan [13]. Group 4: Shareholder and Management Actions - The company’s major shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., confirmed that there are no undisclosed significant matters related to the company, including major asset restructuring or significant transactions [5][8]. - There were no stock trading activities by the company’s directors, senior management, or major shareholders during the period of abnormal stock price fluctuations [8].

经公司书面征询本公司第一大股东内蒙古金宇生物控股有限公司（以下简 称"生物控股"），截至本公告披露日，除在指定信息披露媒体及上海证券交易所 网站上已公开披露的信息外，不存在应披露而未披露的信息。 公司于本公告披露日同日披露了《金宇生物技术股份有限公司关于获得兽 用生物制品临床试验批件的公告》，全资子公司金宇保灵生物药品有限公司（以下 简称"金宇保灵"）收到农业农村部颁发的非洲猪瘟亚单位疫苗临床试验批件。兽 用生物制品在获得临床试验批准后，需要完成临床试验并申报注册，经农业农村部 审评、审批通过获得新兽药证书、兽药产品批准文号后方可上市销售。 证券代码：600201 证券简称：生物股份 公告编号：临2025-044 金宇生物技术股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 金宇生物技术股份有限公司（以下简称"公司"）股票于 2025 年 7 月 15 日、7 月 16 日、7 月 17 日连续 3 个交易日收盘价格涨幅偏离值累计超过 20%。触 及《上海证券交易所交易规则》规 ...

证券代码：600201 证券简称：生物股份 公告编号：临2025-043 金宇生物技术股份有限公司 疫苗产品从前期研发到上市销售整个周期较长，且由于非洲猪瘟病毒免疫机制 的复杂性，本项目在临床试验客观上存在一定的失败风险，项目研究开发进度、技 术成果、后期产业化应用进程等尚存在一定不确定性。根据我国《兽药管理条例》 和《兽药注册办法》的规定，兽用生物制品在获得临床试验批准后，需要完成临床 试验并申报注册，经农业农村部审评、审批通过获得新兽药证书、兽药产品批准文 项目名称 非洲猪瘟亚单位疫苗临床试验 受理号 07020020250417-1 审批结论 同意申请单位在有效期限内在批准的试验地点进行临床试验 申请人 中国科学院生物物理研究所、国药集团动物保健股份有限公 司、金宇保灵生物药品有限公司、中牧实业股份有限公司、 广东蓝玉生物科技有限公司、中国科学院武汉病毒研究所 临床试验承担单位 金宇保灵生物药品有限公司 一、 临床批件主要内容 号后方可上市销售。公司将密切关注后续进展并及时履行信息披露义务，敬请广大 投资者理性投资，注意风险。 特此公告。 金宇生物技术股份有限公司 董 事 会 关于获得兽用生物制品临床试 ...

Core Viewpoint - The company has received clinical trial approval for its African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs, marking a significant step in its vaccine development efforts [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Jinyu Baoling Biological Pharmaceutical Co., Ltd., has been granted the clinical trial approval (Approval No: 2025058) for the African swine fever vaccine [1] - The vaccine is specifically designed to prevent African swine fever virus infections, indicating a targeted approach to addressing this critical issue in the livestock industry [1] - The company has invested approximately 64 million yuan in research and development for this vaccine in collaboration with research institutions since 2023 [1] Group 2: Clinical Trial Process - The clinical trials will be conducted at Jinyu Baoling, and the vaccine must complete these trials and undergo registration application before it can be marketed and sold [1] - Approval from regulatory bodies is required after the completion of clinical trials, highlighting the importance of compliance in the pharmaceutical development process [1]

Group 1 - The company announced that its wholly-owned subsidiary, Jinyu Baoling, received clinical trial approval for an African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs [1] - The vaccine is jointly developed by the Institute of Biophysics of the Chinese Academy of Sciences and China National Pharmaceutical Group Animal Health Co., Ltd., with Jinyu Baoling as the clinical trial undertaking unit [1] - The total research and development investment for the project is approximately 64 million yuan [1] Group 2 - Due to the complexity of the immune mechanism of the African swine fever virus, there is a risk of failure in the clinical trials [1] - The vaccine must complete clinical trials and obtain registration approval before it can be marketed and sold [1] - The company will monitor subsequent developments and fulfill its information disclosure obligations [1]

Group 1: Stock Performance - Zhejiang Zhenyuan and Asia-Pacific Pharmaceutical both achieved a 2-day limit-up with increases of 10.01% and 9.98% respectively, driven by innovation in pharmaceuticals [2] - Chengdu XianDao saw a first board listing with a significant rise of 20.02%, attributed to innovative drug developments [2] - TaiJing Technology and YanHua Intelligent both recorded first board listings with increases of 9.97% and 9.94%, linked to Huawei's influence in robotics [5] Group 2: AI and Robotics - Nvidia's CEO suggested that Huawei's AI chips could potentially replace Nvidia's offerings, indicating a competitive shift in the AI chip market [4] - The domestic robotics industry is gaining traction with significant orders being awarded, highlighting its importance in national competition [7] Group 3: Market Trends - The light communication sector is expected to see sustained growth due to high demand in both domestic and international markets, with performance likely to continue improving [13] - The low-altitude economy is gaining attention, with a notable $1 billion procurement agreement signed for eVTOL aircraft, indicating growth potential in this sector [17] Group 4: Consumer and Retail - The Chinese government is implementing measures to boost consumer spending, which is expected to positively impact the retail sector [21] - Companies like Guoguang Chain and Hanshang Group have seen first board listings with increases of 9.98% and 9.97%, reflecting the positive sentiment in the retail market [23] Group 5: Solar and Food & Beverage - The price of polysilicon has increased by 12.4% week-on-week, indicating a rising trend in the solar industry [24] - The food and beverage sector is also benefiting from government initiatives aimed at enhancing consumer demand, with companies like Huangshi Group seeing a 10.10% increase [26]

Group 1 - The core viewpoint of the articles highlights the rebound in CBOT soybean futures due to anticipated increases in U.S. soybean export demand, particularly following Indonesia's commitment to purchase $4.5 billion worth of U.S. agricultural products [1] - The domestic soybean meal supply is currently ample, which is suppressing upward price movement, while downstream inventory levels are nearing saturation due to previous active replenishment [1] - The A-share market saw a rise in the livestock sector, with notable increases in stocks such as Bio-Group (+8.31%), Luo Niu Shan (+2.09%), and others, indicating a positive market sentiment towards the livestock industry [1] Group 2 - The soybean meal ETF (159985) is recognized not only as a standalone investment but also for its long-term investment value in asset allocation, inflation hedging, and roll yield [2] - Soybean meal has a low correlation with the stock market, suggesting that it can be a strategic long-term allocation even if short-term price increases are uncertain [2] - As the largest production variety among 12 oilseed meal feed types, soybean meal has a solid spot market foundation, enhancing its investment appeal [2]

Policy Developments - Shanghai is advancing the standardization research of medical accompaniment services, with a project led by East China Hospital identified as a key research topic for 2024, focusing on service institutions, personnel requirements, service processes, and quality evaluation [2] Drug and Device Approvals - Maike Bio has received a medical device registration certificate for its coagulation factor activity measurement kits, valid from July 8, 2025, to July 7, 2030, aimed at monitoring treatments for coagulation factor deficiencies [3] - Kewang Pharmaceutical's vitamin K1 drops have received a registration acceptance notice from the National Medical Products Administration, intended to prevent vitamin K deficiency bleeding in infants [4] - CanSino has been approved for clinical trials of its trivalent poliovirus vaccine, which is being developed using protein structure design and VLP assembly technology, currently undergoing I/II phase trials in Indonesia [5] Financial Reports - Johnson & Johnson reported Q2 revenue of $23.74 billion, a 5.8% increase year-over-year, exceeding market expectations, with projected annual sales between $93.2 billion and $93.6 billion [6] Capital Markets - Tuoxin Pharmaceutical plans to invest 10 million yuan in Jiangsu Jinsan Biotechnology Co., acquiring a 1.75% stake, with Jinsan successfully producing high-purity ergothioneine for various products [7] - Tsinghua Unigroup's stock auction resulted in the sale of 58.607 million shares, potentially leading to a change in control of the company, with the shares sold at an average price significantly above the latest closing price [8] Industry Events - China National Pharmaceutical Group responded to rumors regarding the "return" of a licensing agreement with Merck for a PD-1/VEGF bispecific antibody, stating that the collaboration is progressing normally and a milestone payment of $300 million is expected upon completion of technology transfer by 2025 [9] Public Sentiment Alerts - A senior executive of Astellas Pharma in China was sentenced to three and a half years in prison for espionage, highlighting potential risks in the pharmaceutical industry [10] Stock Market Alerts - ST Weiming's stock has been placed under risk warning due to a significant price drop and expected losses of 55 million to 85 million yuan for the first half of 2025, leading to a change in its trading name and restrictions on price fluctuations [11]

Market Overview - On July 16, the Shanghai Composite Index fell by 0.03%, with institutional investors appearing on the trading lists of 25 stocks, net buying 11 and net selling 14 [1][2] - The total net selling amount by institutional investors reached 1.015 billion yuan [1] Institutional Trading Activity - The stock with the highest net buying by institutional investors was Huahong Technology, which closed at the daily limit with a trading volume of 1.919 billion yuan and a turnover rate of 27.83%. The net buying amount was 112.81 million yuan [2][5] - Other notable stocks included Beifang Changlong, which rose by 6.59% with a turnover rate of 42.00% and a net buying amount of 70.49 million yuan [2][5] Performance of Net Bought Stocks - Stocks that were net bought by institutions saw an average increase of 5.35%, outperforming the Shanghai Composite Index. Stocks like Jujie Microfiber and Degute achieved daily limit increases [3] - Historical data indicates that stocks net bought by institutions have a 50.17% probability of rising the next day, with a 37.46% probability of increasing over the next three days [3] Earnings Forecasts - Among the stocks net bought by institutions, four have released half-year earnings forecasts, with Huahong Technology expected to see a net profit increase of 3384.71% [3] Net Sold Stocks - The stock with the highest net selling was C Huaxin, with a net selling amount of 999.70 million yuan. This stock had a significant net inflow of 3.172 billion yuan [3][6] - Annie Shares also saw substantial net selling, amounting to 247.11 million yuan, with a net outflow of 117 million yuan [3][6] Deep and Hong Kong Stock Connect Activity - On July 16, 12 stocks on the trading list had participation from the Shenzhen and Shanghai Stock Connect, with net buying in stocks like Hengbao Co. and Dawi Technology [7][8] - Hengbao Co. had a net buying amount of 160.75 million yuan, while stocks like Zhongdian Port and Qianhong Pharmaceutical experienced net selling [7][9]

Market Overview - A-shares maintained a narrow fluctuation on July 16, with the Shanghai Composite Index closing at 3503.78 points, down 0.03% [1] - The Shenzhen Component Index and the ChiNext Index both fell by 0.22% to 10720.81 points and 2230.19 points, respectively [1] - The total trading volume in the Shanghai and Shenzhen markets was 146.19 billion yuan, a decrease of over 170 billion yuan from the previous day [1] Sector Performance - Financial stocks collectively declined, while the steel, non-ferrous metals, and coal sectors showed weakness [1] - The automotive supply chain stocks surged, with companies like Rongtai Co., Fuda Co., and Zhejiang Rongtai hitting the daily limit [1] - The innovative drug concept saw significant activity, with stocks like Guosheng Tang and Iwu Biotech rising approximately 16% [5][6] - The humanoid robot concept remained hot, with companies like Shangwei New Materials achieving a six-day limit increase [2][4] Notable Company Movements - Huadian New Energy, which debuted on the Shanghai main board, closed up 125.8%, reaching a market value of over 300 billion yuan at one point [1] - Weiyali, a Hong Kong-based electronic component distributor, saw its stock surge by 288% upon resuming trading, with an intraday increase exceeding 900% [1] Humanoid Robot Sector Insights - The humanoid robot industry is in its early stages, with significant growth expected in the next 3 to 5 years across various applications [4] - The current phase is described as the "dawn" of humanoid robot industrialization, with mass production and large-scale application becoming feasible [4] - Cost reduction is crucial for the widespread adoption of humanoid robots, and companies that master core component technologies are recommended for investment [4] Innovative Drug Sector Insights - The innovative drug sector experienced strong gains, with several companies hitting the daily limit [5][6] - The recent launch of the 11th batch of national drug centralized procurement is expected to impact the market, focusing on mature "old drugs" rather than innovative drugs [7] - The introduction of measures to support the high-quality development of innovative drugs indicates a growing role for commercial insurance in the healthcare system [7] Pet Economy Sector Insights - The pet economy concept gained traction, with companies like Weike Technology rising over 10% [8] - The pet food sector is viewed as a growing market with significant long-term growth potential, particularly for domestic brands [8]